在小细胞肺癌中,KDM6A在表观遗传学上调节亚型可塑性
Leslie Duplaquet1, Yixiang Li1, Matthew A Booker2
1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nature cell biology
|August 17, 2023
概括
由于KDM6A的不活化导致小细胞肺癌 (SCLC) 的可塑性从ASCL1转变为NEUROD1亚型. 这种表观遗传调节影响SCLC异质性,为这种具有挑战性的癌症的治疗策略提供了洞察力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 小细胞肺癌 (SCLC) 包含四种分子亚型:ASCL1,NEUROD1,POU2F3和炎症性.
- 虽然最初被认为是不同的,但SCLC亚型表现出瘤内异质性和可塑性.
- 了解亚型可塑性对于开发向性SCLC疗法至关重要.
研究的目的:
- 调查KDM6A/UTX无活化在SCLC亚型可塑性中的作用.
- 阐明ASCL1转换为NEUROD1亚型的表观遗传机制.
- 建立一个相关的小鼠模型来研究SCLC亚型异质性.
主要方法:
- 使用基于CRISPR的本土SCLC基因工程小鼠模型.
- 分析了KDM6A/UTX失活对SCLC亚型特征的影响.
- 检查了染色质状态的变化,包括基因增强剂中的H3K4me1和H3K27me3修饰.
主要成果:
- KDM6A无活化诱导了可塑性,导致SCLC中从ASCL1转向NEUROD1亚型.
- 在KDM6A无活化后发展的瘤表达了ASCL1和NEUROD1标志物.
- 在神经内分泌基因增强剂中,KDM6A的损失降低了H3K4me1并增加了H3K27me3,为亚型切换进行了启动.
结论:
- 已确定KDM6A是控制SCLC中ASCL1-to-NEUROD1亚型可塑性的关键表观遗传调节器.
- 开发的小鼠模型准确地回顾了在人类SCLC中观察到的ASCL1和NEUROD1亚型异质性和可塑性.
- 这些发现为探索针对SCLC表观遗传机制的治疗策略提供了基础.
相关概念视频
Chromatin Modification in iPS Cells
1.7K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.7K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K


